Crossmark

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer

Crossref DOI link: https://doi.org/10.1038/nm.4507

Published Online: 2018-03-26

Published Print: 2018-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nair, Amritha

Chung, Hsiang-Ching

Sun, Tingting

Tyagi, Siddhartha

Dobrolecki, Lacey E

Dominguez-Vidana, Rocio http://orcid.org/0000-0003-3855-5178
Kurley, Sarah J

Orellana, Mayra

Renwick, Alexander

Henke, David M http://orcid.org/0000-0003-2911-2834
Katsonis, Panagiotis

Schmitt, Earlene

Chan, Doug W

Li, Hui

Mao, Sufeng

Petrovic, Ivana

Creighton, Chad J

Gutierrez, Carolina http://orcid.org/0000-0002-2941-3461
Dubrulle, Julien

Stossi, Fabio

Tyner, Jeffrey W

Lichtarge, Olivier

Lin, Charles Y http://orcid.org/0000-0002-9155-090X
Zhang, Bing

Scott, Kenneth L

Hilsenbeck, Susan G

Sun, Jinpeng http://orcid.org/0000-0003-3572-1580
Yu, Xiao

Osborne, C Kent

Schiff, Rachel

Christensen, James G

Shields, David J

Rimawi, Mothaffar F

Ellis, Matthew J

Shaw, Chad A

Lewis, Michael T

Westbrook, Thomas F
License Information

Text and Data Mining valid from 2018-03-26
More Information

Article History

Received: 5 December 2016

Accepted: 29 January 2018

First Online: 26 March 2018

Competing interests

: D.J.S. is an employee of Pfizer. J.G.C. is an employee of Mirati Therapeutics and former employee of Pfizer.